Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites

BMC Cancer

Table 3 Univariable Poisson regression associations with hot flash frequency (3A) and ordinal regression associations with hot flash severity (3B)

3A	Univariable (N = 109)			Inter.	Pre-M. (N = 56)			Post-M & PTHF (N = 18)			Post-M & no PTHF (N = 35)
	Coef	SE	p-value	p-value	Coef	SE	p-value	Coef	SE	p-value	Coef	SE	p-value
Tamoxifen	0.002	0.0024	0.41	0.03	-0.0045	0.004	0.27	0.012	0.0038	0.01	0.0058	0.0044	0.19
N-desmethyltamoxifen	-0.00002	0.0013	0.99	0.13	-0.0013	0.002	0.50	0.0053	0.002	0.02	-0.0014	0.0031	0.66
Endoxifen	-0.015	0.022	0.50	0.01	-0.069	0.03	0.03	0.085	0.028	0.01	-0.0021	0.05	0.97
4-Hydroxytamoxifen	-0.05	0.14	0.73	0.03	-0.3	0.19	0.13	0.63	0.17	0.002	-0.056	0.37	0.88
Post-M & PTHF v pre-M	0.13	0.27	0.67
Post-M & no PTHF v pre-M	-0.14	0.24
Age	-0.0059	0.0098	0.55
Estradiol concentration	-0.12	0.095	0.21
BMI	0.048	0.023	0.04
Tamoxifen duration	0.084	0.087	0.34
CYP2D6: EM versus I/PM	-0.11	0.21	0.61
3B	Univariable (N = 109)			Inter.	Pre-M. (N = 56)			Post-M & PTHF (N = 18)			Post-M & no PTHF (N = 35)
	Coef	SE	p-value	p-value	Coef	SE	p-value	Coef	SE	p-value	Coef	SE	p-value
Tamoxifen	0.0026	0.0045	0.57	0.60	0.0026	0.0065	0.69	0.018	0.014	0.16	0.0019	0.0075	0.80
N-desmethyltamoxifen	-0.00043	0.0022	0.85	0.30	-0.00048	0.003	0.88	0.01	0.0067	0.11	-0.0024	0.0039	0.53
Endoxifen	-0.013	0.039	0.73	0.72	-0.027	0.055	0.62	0.044	0.092	0.63	0.025	0.072	0.73
4-Hydroxytamoxifen	-0.20	0.25	0.43	0.64	-0.11	0.31	0.74	0.39	0.70	0.58	-0.36	0.52	0.48
Post-M & PTHF v pre-M	0.94	0.51	0.11
Post-M & no PTHF v pre-M	-0.17	0.42
Age	-0.018	0.017	0.31
Estradiol concentration	-0.34	0.14	0.02
BMI	0.19	0.048	<0.0001
Tamoxifen duration	0.25	0.18	0.15
CYP2D6: EM versus I/PM	0.0058	0.41	0.99

Inter, Interaction; pre-M, Pre-menopausal patients; post-M, Post-menopausal patients; PTHF, Pre-treatment hot flashes; v, Versus; Coef, Coefficient; SE, Standard error; BMI, Body mass index; EM, Extensive metabolizers; I/PM, Intermediate to poor metabolizers.
For tamoxifen and its metabolites the test of interaction with menopausal and PTHF status, and the within-group associations are also reported.

ISSN: 1471-2407